SCHEMBL1740370

SCHEMBL1740370

N=C(N)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.63
MEN1 O00255 5/20 0.63
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TGM2 P21980 1/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
MAPT P10636 2/20 0.53
MAPK1 P28482 2/20 0.53
POLB P06746 2/20 0.53
NAMPT P43490 1/20 0.53
MITF O75030 1/20 0.53
GAA P10253 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MYOC Q99972 1/20 0.53
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.50
IDO1 P14902 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7258086 0.98 KMT2A (0.61) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
Nitric Acid SCHEMBL3860512 0.96 KMT2A (0.59) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
Acetic Acid SCHEMBL27811416 0.92 KMT2A (0.59) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
Benzoic Acid SCHEMBL3748811 0.86 MEN1 (0.64) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1
SCHEMBL1740901 0.86 KMT2A (0.56) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
SCHEMBL11137991 0.84 MEN1 (0.69) KMT2AMEN1SMN1; SMN2TGM2NPC1
Hydrochloric Acid SCHEMBL21645347 0.84 KMT2A (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
SCHEMBL16470335 0.84 KMT2A (0.68) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
Hydrochloric Acid SCHEMBL4361436 0.83 MEN1 (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2TGM2
4-Guanidino-Benzoic Acid SCHEMBL27610956 0.83 MEN1 (0.64) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0517852-B1 TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS OREGON STATE (US) 2002-07-10 EP claimed
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product NITTO KASEI CO., LTD. (JP) 2025-11-25 US disclosed
EP-4174053-B1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO LTD (JP) 2025-11-19 EP disclosed
EP-4569023-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2025-06-18 EP disclosed
CN-115516041-B Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product 日东化成株式会社 2024-06-28 CN disclosed
WO-2024033348-A1 COMBINATION OF CATALYTIC COMPONENTS POLYU GMBH (DE) 2024-02-15 WO disclosed
EP-4321573-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2024-02-14 EP disclosed
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO., LTD. (JP) 2023-07-27 US disclosed
EP-4180482-A1 MOISTURE-CURABLE COMPOSITION Nitto Kasei Co., Ltd. (JP) 2023-05-17 EP disclosed
US-20090186993-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-23 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-7459448-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
EP-1990371-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-12 EP disclosed
EP-1228058-A4 BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DONGBU HANNONG CHEMICAL CO LTD (KR) 2003-02-12 EP disclosed
EP-1228058-A1 BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dongbu Hannong Chemical Co., Ltd. (KR) 2002-08-07 EP disclosed
WO-2001029023-A1 BENZOPYRANYL GUANIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2001-04-26 WO disclosed
US-5395747-A Polylactones as stabilizers in antihalation systems where an anion is thermally generated to decolor dyes formed by scattered light MINNESOTA MINING & MANUFACTURING COMPANY (US) 1995-03-07 US disclosed
US-5324627-A Thermal carbanion generating agent MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product KDM2B, SETDB1, ASH2L KMT2A 150/4885MEN1 684/4885ALDH1A1 615/4885
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885ALDH1A1 4635/4885
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT KDM2B, SETDB1, ASH2L KMT2A 150/4885MEN1 684/4885ALDH1A1 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.